Laminar Pharmaceuticals S.A. has announced that the last participant has completed the final scheduled visit in its Phase 2b/3 trial of LAM561, an investigational oral therapy being evaluated alongside radiotherapy and temozolomide in adults with newly diagnosed, IDH-wildtype glioblastoma. The operational milestone ends the study’s active clinical monitoring phase and moves the programme into data cleaning, database lock and final analysis, with Laminar Pharma expecting topline results during the second quarter of 2027.
The announcement does not establish that LAM561 improves survival, nor does it provide new efficacy results. Its significance is that the company now appears to have collected the patient-level follow-up required to analyse the trial’s primary overall survival endpoint after the study reached its planned threshold of 90 overall survival events.
That distinction is particularly important because Laminar Pharma previously disclosed an encouraging progression-free survival trend in a molecularly defined subgroup, while acknowledging that the interim comparison across the overall trial population did not meet its prespecified progression-free survival target. The programme has therefore reached the point at which a mature, randomised overall survival analysis must determine whether the earlier signal represents a clinically important treatment effect or an interesting subgroup observation that cannot support broader conclusions.
Why does the last-patient-last-visit milestone matter without providing new efficacy data?
Last-patient-last-visit is primarily a clinical trial execution milestone. It indicates that the final participant has completed the protocol-defined follow-up required for the planned analysis, allowing the sponsor and its clinical research teams to reconcile outstanding records, verify endpoint events, resolve data queries and prepare the database for locking.
For Laminar Pharma, this removes one source of timing uncertainty around the CLINGLIO study. The company said the trial has reached the 90 overall survival events needed to trigger the final survival analysis, although the projected topline disclosure has moved to the second quarter of 2027. The interval between the final visit and topline results reflects the work still required to validate the dataset and conduct the prespecified statistical analysis.
The milestone should therefore be viewed as evidence that the trial is progressing toward readout, rather than evidence that the treatment has succeeded. No conclusion about efficacy can be drawn merely because follow-up has ended, and the absence of a new safety warning in the announcement does not provide a complete assessment of the final safety dataset.
The study’s event-driven design also means calendar timing has been less important than the accumulation of deaths needed for the overall survival analysis. Once the required events were recorded and the remaining participant follow-up was completed, the programme could progress toward its decisive statistical evaluation.
How was the LAM561 Phase 2b/3 glioblastoma trial designed to test clinical benefit?
CLINGLIO, registered as NCT04250922, is an international, multicentre, randomised, placebo-controlled Phase 2b/3 study involving 144 adults with newly diagnosed, IDH-wildtype glioblastoma. Participants were assigned in a one-to-one ratio to receive either LAM561 plus standard treatment or placebo plus standard treatment. The study remained double-blind until the completion of its interim analysis and subsequent decision to unblind the trial.
The standard-treatment backbone consists of radiotherapy and temozolomide, followed by maintenance temozolomide. Participants in the experimental group received 12 grams of LAM561 per day, while the control group received a matching placebo. After the temozolomide maintenance period, the protocol continued LAM561 or placebo as monotherapy.
Overall survival is the principal efficacy measure for the final analysis, with progression-free survival assessed using Response Assessment in Neuro-Oncology criteria. Overall survival is a demanding but clinically meaningful endpoint because it measures whether patients receiving the investigational therapy live longer, rather than relying only on imaging-based evidence that tumour progression has been delayed.
The randomised and placebo-controlled design gives the trial considerably greater evidentiary weight than Laminar Pharma’s earlier development studies. However, the relatively modest enrolment means the magnitude and consistency of any survival difference will matter. A result driven by a small number of patients, an exploratory subgroup or an imbalance in subsequent treatments would require particularly careful interpretation.
Why must the earlier MGMT-methylated progression-free survival signal remain provisional?
Laminar Pharma disclosed interim unblinded findings in March 2025 after an independent data monitoring committee recommended that the trial continue without modification until the required 90 overall survival events had occurred. The committee also recommended unblinding the study following the interim review.
At that point, the company acknowledged that the prespecified progression-free survival objective, described as a hazard ratio of 0.5, had not been achieved in the overall trial population. Laminar Pharma subsequently highlighted a more favourable trend among participants whose tumours had methylated MGMT promoters. In the company’s interim snapshot, median progression-free survival was reported at 86.4 weeks for the LAM561 group and 54.7 weeks for the placebo group in that subgroup, with a hazard ratio of 0.53.
The company explicitly described that analysis as not statistically assessed and subject to continuing review. It should not be treated as definitive evidence that LAM561 benefits patients with MGMT-methylated tumours.
MGMT promoter methylation is clinically relevant because it is associated with greater sensitivity to temozolomide. It may also identify patients with a different underlying prognosis. These factors make stratified analysis scientifically important, but they also mean that an apparently strong result in the methylated population must be interpreted against the trial’s statistical plan, subgroup size and interaction between treatment effect and biomarker status.
The final dataset will need to show whether any progression-free survival advantage is accompanied by longer overall survival. It will also be important to determine whether the effect is present across the full enrolled population or concentrated in a prespecified biomarker group.
A positive subgroup finding can support a more targeted regulatory development strategy, particularly when the biological and clinical rationale is credible. It cannot automatically rescue an unsuccessful primary analysis unless the trial’s statistical framework and regulatory discussions support that interpretation.
What does LAM561’s membrane-focused mechanism add to the glioblastoma treatment hypothesis?
LAM561, also known as idroxioleic acid sodium or 2-hydroxyoleic acid, is a synthetic hydroxylated derivative of oleic acid. Laminar Pharma is developing the molecule through its membrane lipid therapy platform, which seeks to alter the lipid composition and organisation of cancer-cell membranes.
The proposed mechanism differs from conventional cytotoxic chemotherapy and many targeted oncology drugs. Laminar Pharma’s scientific hypothesis is that modifying the tumour-cell membrane can disrupt membrane-associated signalling, influence sphingolipid metabolism and mitochondrial function, and promote autophagy-related cancer-cell death.
Mechanistic novelty is commercially attractive in glioblastoma because the disease has resisted numerous approaches that appeared persuasive in laboratory studies. It is not, however, a substitute for demonstrating survival benefit in a controlled clinical trial.
The earlier Phase 1/2A study of idroxioleic acid was an open-label, non-randomised trial involving 54 patients with glioma or other advanced solid tumours. The study established 12 grams per day as the recommended Phase 2 dose after gastrointestinal dose-limiting toxicities were observed at higher doses and in one participant receiving the selected dose. The most frequently reported treatment-related events were generally lower-grade nausea, vomiting and diarrhoea.
Among 21 participants with recurrent high-grade glioma, five met the study’s definition of clinical benefit, which included complete response, partial response or stable disease lasting beyond six treatment cycles. One participant experienced a prolonged response lasting more than two and a half years.
Those findings provided a rationale for further development but came from a heterogeneous, heavily pretreated population without a randomised control arm. The current Phase 2b/3 trial is the first test capable of determining whether adding LAM561 to initial glioblastoma treatment produces a reproducible benefit beyond radiotherapy and temozolomide.
How should the reported tolerability be assessed when the final safety dataset is unavailable?
Laminar Pharma said the combination’s safety profile remained consistent with earlier studies and described LAM561 plus standard treatment as well tolerated across the 144 enrolled participants. The company did not provide detailed rates of serious adverse events, grade 3 or higher events, dose interruptions, discontinuations or treatment-related deaths in its last-patient-last-visit announcement.
The absence of a disclosed new safety signal is reassuring at an operational level, particularly because the independent monitoring committee previously recommended continuing the study without modification. It does not allow a full benefit-risk assessment.
Final interpretation will require adverse events to be examined alongside exposure duration, adherence and the toxicity already associated with radiotherapy and temozolomide. Gastrointestinal tolerability may be commercially relevant because the daily LAM561 dose is substantial and the programme is intended for treatment over an extended period.
The Phase 1/2A study also found that adherence to the intended dose was imperfect across treatment cycles. Although adherence patterns in an advanced, heavily pretreated population cannot be directly transferred to newly diagnosed patients, they underline the importance of evaluating whether participants in CLINGLIO could consistently take the planned oral dose.
A therapy can demonstrate biological activity yet struggle in practice when formulation burden, gastrointestinal effects or complex dosing reduce long-term exposure. The final analysis should therefore be assessed not only for adverse-event frequency but also for dose intensity, discontinuations and the amount of treatment patients actually received.
Could the unblinding and compassionate-use continuation complicate interpretation?
Following the interim review, the trial was unblinded, allowing patients, investigators and the sponsor to learn treatment assignments. Laminar Pharma said patients considered by their treating physicians to be deriving clinical benefit could continue receiving LAM561 through a compassionate-use programme after completing the study.
Continued access may be ethically appropriate for patients whose physicians believe stopping treatment would be undesirable. However, unblinding and post-trial access create analytical considerations that will need to be transparently addressed when the final results are released.
Overall survival is less vulnerable to subjective assessment than radiographic progression, but knowledge of treatment allocation can influence subsequent care, follow-up decisions and the timing or selection of later therapies. The company will need to explain how the statistical analysis deals with post-protocol treatment, censoring and any crossover-like exposure.
Progression-free survival interpretation may be more sensitive because radiographic evaluation in glioblastoma can be complicated by treatment-related changes that resemble tumour progression. The use of Response Assessment in Neuro-Oncology criteria and independent review procedures will therefore matter when the complete evidence package is assessed.
The compassionate-use programme should not be interpreted as independent confirmation that LAM561 is effective. Eligibility appears to be based on treating-physician judgement of individual clinical benefit, rather than on a separate controlled analysis.
What regulatory and commercial questions would follow a positive overall survival result?
LAM561 has received European Union orphan medicinal product designation for the treatment of glioma. The European Medicines Agency makes clear that orphan designation provides development incentives and regulatory support but is not a marketing authorisation or confirmation that a therapy is effective.
Laminar Pharma has also reported receiving United States Food and Drug Administration Fast Track designation for glioblastoma. These designations could facilitate regulatory interaction, but the company would still need to submit a complete package covering efficacy, safety, manufacturing quality and the proposed patient population.
The regulatory path would depend heavily on the final overall survival result. A statistically persuasive and clinically meaningful benefit across the full intention-to-treat population would provide the clearest basis for marketing applications. A benefit restricted to MGMT-methylated patients could instead require a narrower biomarker-defined development strategy.
Regulators would also examine whether the Phase 2b/3 design, sample size and analysis plan are sufficient to support authorisation without another confirmatory trial. The answer may depend on the size of the effect, consistency across secondary endpoints, safety and the credibility of subgroup findings.
Commercial readiness presents another layer. Laminar Pharma is a privately held biotechnology company that has openly sought investment and development partners for LAM561. A positive survival readout could materially improve the programme’s licensing position, while an ambiguous result would make partnership discussions more difficult.
Formulation and manufacturing will also require attention. Laminar Pharma has disclosed a publicly financed project intended to improve the existing powder-for-oral-suspension formulation and support industrial-scale manufacturing. That work is strategically important because a high daily oral dose must be produced reliably, administered conveniently and tolerated over long treatment periods.
What must the second-quarter 2027 LAM561 readout establish to change the programme’s outlook?
The most important figure will be the overall survival hazard ratio, accompanied by its confidence interval, statistical significance and median survival estimates for each trial group. The absolute difference in survival will be as important as the relative risk reduction because clinicians and regulators must judge whether the magnitude is meaningful for patients.
The readout should also disclose progression-free survival in the intention-to-treat population, prespecified MGMT subgroups and other stratification categories. Any subgroup result will need to be evaluated for sample size, consistency, interaction testing and whether the analysis was prespecified.
Safety reporting should include serious and high-grade adverse events, treatment discontinuations, dose reductions, interruptions and treatment-related deaths. Exposure and adherence will help determine whether LAM561 can be integrated into a demanding chemoradiotherapy regimen without adding an impractical treatment burden.
Laminar Pharma has completed the operational phase needed to answer these questions, but the programme remains investigational and its central clinical hypothesis is unresolved. The earlier MGMT-methylated progression-free survival trend gives the 2027 readout additional scientific interest, while the unsuccessful overall-population interim PFS comparison reinforces the need for restraint.
A convincing overall survival result would give membrane lipid therapy its strongest clinical validation and could move LAM561 toward regulatory submissions and commercial partnering. A weak, inconsistent or subgroup-dependent result would leave the company with a much harder task, regardless of how intriguing the mechanism or earlier signals appear. The last patient has completed the last visit, but for LAM561, the decisive test has only just begun.
